19 related articles for article (PubMed ID: 11766367)
1. A randomized comparative study of endocrine monotherapy and a combination of estramustine phosphate with the endocrine therapy in patients with untreated stage D prostate cancer.
Hoshi S; Yamaguchi O; Fujioka T; Arai Y; Tomita Y; Habuchi T; Ohyama C; Suzuki T; Orikasa S;
Int J Clin Oncol; 2006 Aug; 11(4):303-8. PubMed ID: 16937304
[TBL] [Abstract][Full Text] [Related]
2. Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.
Noguchi M; Noda S; Yoshida M; Ueda S; Shiraishi T; Itoh K;
Int J Urol; 2004 Feb; 11(2):103-9. PubMed ID: 14706014
[TBL] [Abstract][Full Text] [Related]
3. Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Meluch AA; Spigel DR; Yost K; Meng C; Greco FA
Clin Genitourin Cancer; 2006 Mar; 4(4):287-92. PubMed ID: 16729913
[TBL] [Abstract][Full Text] [Related]
4. Combination treatment versus LHRH alone in advanced prostatic cancer.
Ferrari P; Castagnetti G; Ferrari G; Baisi B; Dotti A
Urol Int; 1996; 56 Suppl 1():13-7. PubMed ID: 8776812
[TBL] [Abstract][Full Text] [Related]
5. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
Nelius T; Klatte T; Yap R; Kalinski T; Röpke A; Filleur S; Allhoff EP
BJU Int; 2006 Sep; 98(3):580-5. PubMed ID: 16925757
[TBL] [Abstract][Full Text] [Related]
6. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
Nelius T; Reiher F; Lindenmeir T; Klatte T; Rau O; Burandt J; Filleur S; Allhoff EP
Onkologie; 2005 Nov; 28(11):573-8. PubMed ID: 16249643
[TBL] [Abstract][Full Text] [Related]
7. [Clinical efficacy of leuprolide acetate and combined treatment with estramustine for advanced prostate cancer].
Saito S; Nakashima J; Nakajima Y; Ikeuchi K; Shibayama T; Nagakura K; Naide Y; Hayakawa M; Ogawa Y; Hata M; Nakazono M; Hasegawa S; Oda T; Kimura S; Nakamura S; Matsunaga J; Fujioka T; Tanoguchi H; Aoki S; Yamamoto Y; Izawa A; Kimura S; Suzuki K; Tazaki H; Murai M;
Nihon Hinyokika Gakkai Zasshi; 2001 Nov; 92(7):682-93. PubMed ID: 11766367
[TBL] [Abstract][Full Text] [Related]
8. [Intermittent oral hormonal chemotherapy using estramustine phosphate and etoposide for the treatment of hormone-refractory prostate cancer].
Kimura M; Sasagawa T; Tomita Y; Katagiri A; Morishita H; Saito T; Tanikawa T; Kawasaki T; Saito K; Nishiyama T; Kasahara T; Hara N; Takahashi K
Hinyokika Kiyo; 2003 Dec; 49(12):709-14. PubMed ID: 14978952
[TBL] [Abstract][Full Text] [Related]
9. [Combined hormone/chemotherapy for advanced prostatic cancer].
Komatsu H
Nihon Hinyokika Gakkai Zasshi; 1997 Mar; 88(3):375-85. PubMed ID: 9125860
[No Abstract] [Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
